Therefore, LUSC and lung adenocarcinoma should be discussed separately in terms of adjuvant clinical implementations, and patients with driver gene mutations, including EGFR sensitive mutations or ALK fusions, were excluded from the present study in order to eliminate the systematic bias. The gene discussed is EGFR; the disease is lung adenocarcinoma.